Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Novel Targeted Therapies in Brain Tumors
share announcement

Novel Targeted Therapies in Brain Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1660

Special Issue Editors

Prof. Dr. Maria Caffo

E-Mail Website
Guest Editor
Unit of Neurosurgery, Department of Biomorphology and Dental Sciences, and Morphofunctional Imaging, University of Messina, AOU “G. Martino”, Messina, Italy
Interests: neurooncology; brain tumors; glioma; target-therapy; meningioma; neurosurgery
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Emanuela Esposito

E-Mail Website
Guest Editor
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98122 Messina, Italy
Interests: neuroinflammation; neuromodulation; astrocytes; spinal cord injury; brain trauma; cytokines; neurodegenerative disorders; brain tumors
Special Issues, Collections and Topics in MDPI journals
Dr. Paola Gaviani

E-Mail Website
Guest Editor
Neuro Oncology Unit, Neuro Oncology Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milano, Italy
Interests: neurooncology; brai tumors; gliomas; systemic and target chemotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Brain tumors are a heterogeneous group of neoplasms, the most common being gliomas, that differ in their spectrum of behavior, from those which are relatively benign to the most malignant, glioblastoma multiforme. Due to their micro-environment within the central nervous system, and due to the presence of blood–brain barrier, blood–cerebrospinal fluid barrier, and blood–tumor barrier, brain tumors are well isolated from systemic circulation. For this reason, systemic therapy has been mostly unsuccessful. However, brain tumors no longer carry the same prognosis as they did some years ago. Improvements in surgery can related with this view as well as for the other innovative therapies combined with surgery.

The possibility of targeted therapies, which spare normal tissue and destroy tumor cells, is changing the field of Neuro-Oncology, with significant impact on the treatment of malignant brain tumors in the near future. These treatments do their effect principally with two mechanisms. One group is monoclonal antibodies which block receptors of the cell surface, deliver antineoplastic agents or facilitate the immune response. A second group of agents are small molecules which enter the cells and interrupt signaling pathways that are important for neoplasms growth. Therefore, comprehensive approaches are needed to achieve maximally from promising targeted therapies. Common methods used for crucial evaluation of targeted therapies for brain tumors involve: novel methods for targeted delivery of chemotherapy and strategies for delivery through BBB and blood-tumor barriers; a better understanding of personalized/precision medicine approaches to therapy in clinical trials and translation into practice of neurosurgery and neuro-oncology, suggests optimism for the future management of brain tumors.

We are pleased to invite you collaborate and work with us to send your article, research, trials or review on these above mentioned subjects.

This Special Issue aims to focus about novel aspects of precision medicine in Neuro-oncology, targeted and immunotherapy, clinical research specific open clinical trials and comprensive  reviews.

In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Current Oncology.

Prof. Dr. Maria Caffo
Prof. Dr. Emanuela Esposito
Dr. Paola Gaviani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision-medicine
  • targeted-therapy
  • brain tumors
  • immunotherapy
  • glioma
  • meningioma

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 333 KiB  
Review
Novel Advances in Treatment of Meningiomas: Prognostic and Therapeutic Implications
by Gerardo Caruso, Rosamaria Ferrarotto, Antonello Curcio, Luisa Metro, Francesco Pasqualetti, Paola Gaviani, Valeria Barresi, Filippo Flavio Angileri and Maria Caffo
Cancers 2023, 15(18), 4521; https://doi.org/10.3390/cancers15184521 - 12 Sep 2023
Cited by 1 | Viewed by 1148
Abstract
Meningiomas are the most frequent histotypes of tumors of the central nervous system. Their incidence is approximately 35% of all primary brain tumors. Although they have the status of benign lesions, meningiomas are often associated with a decreased quality of life due to [...] Read more.
Meningiomas are the most frequent histotypes of tumors of the central nervous system. Their incidence is approximately 35% of all primary brain tumors. Although they have the status of benign lesions, meningiomas are often associated with a decreased quality of life due to focal neurological deficits that may be related. The optimal treatment is total resection. Histological grading is the most important prognostic factor. Recently, molecular alterations have been identified that are specifically related to particular phenotypes and, probably, are also responsible for grading, site, and prognostic trend. Meningiomas recur in 10–25% of cases. In these cases, and in patients with atypical or anaplastic meningiomas, the methods of approach are relatively insufficient. To date, data on the molecular biology, genetics, and epigenetics of meningiomas are insufficient. To achieve an optimal treatment strategy, it is necessary to identify the mechanisms that regulate tumor formation and progression. Combination therapies affecting multiple molecular targets are currently opening up and have significant promise as adjuvant therapeutic options. We review the most recent literature to identify studies investigating recent therapeutic treatments recently used for meningiomas. Full article
(This article belongs to the Special Issue Novel Targeted Therapies in Brain Tumors)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Brain tumors are a heterogeneous group of neoplasms, the most common being gliomas, that differ in their spectrum of behavior, from those which are relatively benign to the most malignant, glioblastoma multiforme. Due to their micro-environment within the central nervous system, and due to the presence of blood–brain barrier, blood–cerebrospinal fluid barrier, and blood–tumor barrier, brain tumors are well isolated from systemic circulation. For this reason, systemic therapy has been mostly unsuccessful. However, brain tumors no longer carry the same prognosis as they did some years ago. Improvements in surgery can related with this view as well as for the other innovative therapies combined with surgery.

The possibility of targeted therapies, which spare normal tissue and destroy tumor cells, is changing the field of Neuro-Oncology, with significant impact on the treatment of malignant brain tumors in the near future.

This Special Issue aims to focus about novel aspects of precision medicine in Neuro-oncology, targeted and immunotherapy, clinical research specific open clinical trials and comprensive  reviews.

Back to TopTop